Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.

Peter H J SlootbeekIris S H KlootsMinke SmitsInge M van OortWinald R GerritsenJack A Schalken Marjolijn J L LigtenbergKatrien GrünbergLeonie I KroezeHaiko J BloemendalNiven Mehra

Published in: British journal of cancer (2021)

Recommendation for a GMT is achieved in almost half of the patients with advanced prostate cancer, with GMT initiation leading to durable responses in over 40% of patients. These data justify routine referral of selected PCa patients to MTB's.

Keyphrases

prostate cancer
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
primary care
machine learning
big data
patient reported